

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Faricimab for treating macular oedema caused by
retinal vein occlusion**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| N/A – none identified |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| Stakeholders commented that if a person is registered as blind or partially sighted they are considered disabled, as stated in the Equality Act 2010. Therefore, the patient population addressed in this submission is a protected group under this act.

One stakeholder commented that age needed to be considered.

The committee recognised that the patient population of this appraisal is a protected group under the Equality Act of 2010 but the equality issues were not relevant to the recommendations. |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

None

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

No equalities issues identified. Not usually described in cost-comparison appraisal unless significant discussions.

Approved by Associate Director (name): Ross Dent

Date: 01/07/2024